Grifols, a global healthcare company and producer of plasma-derived medicines, has shared positive results from its phase 2/3 clinical trial (NCT02176863) evaluating the efficacy and safety of Grifols intravenous immunoglobulin (IVIG) to treat patients with post-polio syndrome (PPS), demonstrating a significant improvement in distance walked compared to placebo. PPS can emerge decades after an initial polio infection. Symptoms – including chronic fatigue, joint and muscle pain, persistent and...